Under the terms Stemline will provide Insilico with an upfront payment of $20 million. The total value of the
transaction is more than $550 million, including all development, regulatory and commercial milestones, with tier royalties to follow.
Prior to this collaboration, Menarini Group and Insilico sign an exclusive licensing agreement in
January 2024 for MEN2312: MEN2312 is an sao tome and principe email list 150000 contact leads innovative small molecule drug for the treatment of
breast cancer and other oncology indications.
MEN2312 Introduction
Design by Insilico’s R&D team with the assistance of its end-to-end pharmaceutical generation AI
platform, MEN2312 can block endocrine receptors (ER) at the transcriptional level, giving it the
potential to overcome resistance to endocrine therapy due to mutations or ligand-independent
constitutive activation of ER. In preclinical studies, this molecule has been shown to have a potent
inhibitory effect on KAT6 in a variety of CDX and PDX models, with good efficacy and high safety.
About Menarini Group
Menarini Group is a leading international pharmaceutical and diagnostics company with revenues in
excess of US$ 4.7 billion and over 17,000 employees. Menarini user experience first focuses on developing products in areas
of unmet therapeutic ne, including cardiology, oncology, respiratory micine, gastroenterology,
infectious diseases, diabetes, inflammation and analgesia. Menarini has 18 production sites and 9 R&D
centers, and its products are sold in 140 countries around the world. For more information, please visit Menarini.
About Stemline Therapeutics Inc
Stemline Therapeutics, Inc. (“Stemline”), a wholly own subsidiary of Menarini Group, is a commercial-
stage biopharmaceutical company focus on the development and commercialization of novel oncology
therapeutics. Stemline launches ORSERDU® (elacestrant) in the US and EU, an oral endocrine
therapy for the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth
factor receptor 2 (HER2)-negative, ESR1-mutat advanc calling list or metastatic breast cancer whose disease has
progress after at least one line of endocrine therapy. Stemline also launch ELZONRIS® (tagraxofusp-
erzs) in the U.S. and Europe, an innovative target therapy for CD123, for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive blood cancer Under the terms.